Previous 10 | Next 10 |
Lipocine (NASDAQ: LPCN ): Q3 GAAP EPS of -$0.12 beats by $0.11 . More news on: Lipocine Inc., Earnings news and commentary, , Read more ...
SALT LAKE CITY , Nov. 12, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter and nine months ended September 30, 2019 , and provided a corporate update. Third Quarter and Re...
Gainers: Taronis Technologies (NASDAQ: TRNX ) +43% . More news on: Taronis Technologies, Inc., Carbonite, Inc., Jounce Therapeutics, Inc., Stocks on the move, Read more ...
Lipocine (NASDAQ: LPCN ) -77% after FDA rejects second Tlando application. More news on: Lipocine Inc., NextCure, Inc., Foamix Pharmaceuticals Ltd., Stocks on the move, Read more ...
Lipocine (NASDAQ: LPCN ) has received a second Complete Response Letter (CRL) from the FDA regarding its refiled marketing application for testosterone replacement therapy candidate Tlando. More news on: Lipocine Inc., Healthcare stocks news, Stocks on the move, Read more ...
SALT LAKE CITY , Nov. 11, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA") regarding its New Drug Applicat...
These 5 Penny Stocks On Robinhood Are Anticipating Results This Week When you talk to someone about penny stocks , you generally see two, very different responses. Typically for those who are either new to these low priced stocks or who’ve lost money in the past, they presume penny st...
SALT LAKE CITY , Oct. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will participate in a panel presentation at the B. Riley "NASH-ing in, Let's All Dig i...
SALT LAKE CITY , Oct. 10, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will provide a corporate overview at the H.C. Wainwright 3 rd Annual NASH Investor Conference, be...
SALT LAKE CITY , Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") will be pre...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...